A detailed history of Rock Springs Capital Management LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Rock Springs Capital Management LP holds 1,103,778 shares of CLDX stock, worth $27.3 Million. This represents 1.28% of its overall portfolio holdings.

Number of Shares
1,103,778
Previous 1,398,994 21.1%
Holding current value
$27.3 Million
Previous $51.8 Million 27.58%
% of portfolio
1.28%
Previous 1.61%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$32.06 - $44.56 $9.46 Million - $13.2 Million
-295,216 Reduced 21.1%
1,103,778 $37.5 Million
Q2 2024

Aug 14, 2024

BUY
$32.76 - $42.56 $878,262 - $1.14 Million
26,809 Added 1.95%
1,398,994 $51.8 Million
Q1 2024

May 15, 2024

BUY
$35.22 - $51.88 $14.2 Million - $20.9 Million
402,539 Added 41.51%
1,372,185 $57.6 Million
Q4 2023

Feb 14, 2024

BUY
$22.61 - $40.65 $10.6 Million - $19.1 Million
469,545 Added 93.89%
969,646 $38.5 Million
Q3 2023

Nov 14, 2023

BUY
$25.45 - $37.46 $2 Million - $2.94 Million
78,486 Added 18.62%
500,101 $13.8 Million
Q2 2023

Aug 14, 2023

BUY
$30.29 - $38.28 $3,362 - $4,249
111 Added 0.03%
421,615 $14.3 Million
Q4 2022

Feb 14, 2023

SELL
$27.78 - $45.38 $2,778 - $4,538
-100 Reduced 0.02%
421,504 $18.8 Million
Q3 2022

Nov 14, 2022

BUY
$22.7 - $37.57 $1.96 Million - $3.24 Million
86,127 Added 25.67%
421,604 $11.9 Million
Q2 2022

Aug 15, 2022

BUY
$20.5 - $37.33 $4.88 Million - $8.89 Million
238,160 Added 244.73%
335,477 $9.04 Million
Q1 2022

May 16, 2022

BUY
$27.64 - $39.32 $2.69 Million - $3.83 Million
97,317 New
97,317 $3.32 Million

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.16B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Rock Springs Capital Management LP Portfolio

Follow Rock Springs Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.